PresidentMr. Glenn SaldanhaChairman & Managing Director, Glenmark Pharmaceuticals Limited
Mr. Glenn Saldanha is the Chairman & Managing Director of Glenmark Pharmaceuticals Ltd. He joined in 1998 as Director and took over as Managing Director & CEO in 2001.
As Chairman & Managing Director of the Company, Mr. Saldanha oversees all operations of the organization. During his tenure, he transformed Glenmark into a truly global organization with revenue in excess of Rs 9000 crores (USD 1.4 billion) and offices in more than 40 countries worldwide. Under his leadership, Glenmark has evolved from an Indian branded generics business, into a research-driven and innovation-led organization. Mr. Saldanha's vision is to discover, develop and take to market India's first innovative drug for the entire world.
Mr. Saldanha holds a bachelor's degree in pharmacy from Mumbai University and is an MBA from the Leonard Stern School of Business at New York University. Prior to Glenmark, he has worked with Eli Lily, USA and PriceWater House Coopers, USA.
Dr Rajesh Jain
Joint Managing Director, Panacea Biotec
Dr. Rajesh Jain is Joint Managing Director of Panacea Biotec, a leading Biotechnology Company employing over 2,500 people. He provides strategic leadership, management and guidance to the company. He has extensive experience and qualifications in biotechnology and is responsible for Innovation and Business Development.
Dr Jain is an active member of major industry associations and government panels. He is a Co-Chair Confederation of Indian Industry (CII), National Committee on Biotechnology for 2017-18. He is a member of Central Drug Research Institute (CDRI), Lucknow. Dr Jain is a recipient of many awards such as India Innovation Award for 2016 and 2015 by Clarivate Analytics and has been appreciated by GAVI and Bill and Melinda Gates Foundation for his commitment towards making affordable vaccines for population across the globe.
Dr Jain is a science graduate and holds a PhD in Management. He has authored two position papers for CII: Guideline Changes in Vaccine Approval Procedures and Regulatory & Policy Changes for Sustained Competitiveness of the Indian Vaccine Industry.
Mr. Dilip G Shah
Vision Consulting Group
Mr. Dilip G. Shah graduated from the premier business school in India, the Indian Institute of Management (IIM), Ahmedabad. He has 50 years of varied experience in the pharmaceutical industry. He has addressed several WTO workshops on TRIPS, WIPO seminars on IPRs and Public Health, WHO meetings on Access to Medicines and several other international meetings and conferences. He was a Member of the official Indian Delegation to WTO Ministerial Conference in Cancun. He also appeared before the U.S. International Trade Commission (USITC) and testified in Investigation No.332-543 Hearing in Washington DC in 2014.
Currently, he is the Secretary-General of the Indian Pharmaceutical Alliance (www.ipa-india.org), Member of the Expert Review Committee on Access to Medicine (ATM) Index (www.atmindex.org); Member of the CPhI International Advisory Board; Member of the Board of Advisors of Pharmabiz.com (Weekly); and Member of Task Forces and Expert Groups constituted by the Government of India for accelerating growth of the Indian pharmaceutical industry. He was Chair of the International Generic Pharmaceutical Alliance (IGPA) for two terms (2005-07) and (2010-11).
Mr. Shah is an independent director on the Boards of Fresenius Kabi Oncology Ltd and Anuh Pharma Ltd and CEO of Vision Consulting Group (www.vision-india.com), a firm specialized in strategic planning. Before starting Vision in 1997, he was a Member of the Board of Directors of Pfizer-India for whom he worked for 30 years.